# Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Study · id `cardio:ct-nct03587558` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03587558](<https://clinicaltrials.gov/study/NCT03587558>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03587558

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

## Technical summary

Registry record NCT03587558. Randomized; no masking; primary purpose treatment. Start 2017-09-05 (actual); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT03587558, source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)
- Started: 2017-09-05 (actual) (ClinicalTrials.gov record NCT03587558, source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03587558, source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03587558, source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03587558, source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03587558-2018-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
- Acronym: FOREVER
- Condition: Ventricular Premature Complexes
- Condition: Outflow Tract
- Condition: Carvedilol
- Intervention (Drug): Carvedilol
- Intervention (Drug): Flecainide
- Lead sponsor: Keimyung University Dongsan Medical Center
- Lead sponsor class: OTHER
- Collaborator: Chong Kun Dang Pharmaceutical Corp.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Premature heartbeats (`cardio:premature-heartbeats`)
- Registry intervention name matches this record: Carvedilol (`cardio:carvedilol`)
- Registry lists this organization as the lead sponsor: Keimyung University Dongsan Medical Center (`cardio:org-keimyung-university-dongsan-medical-center`)
- Registry lists this organization as a collaborator: Chong Kun Dang Pharmaceutical Corp. (`cardio:org-chong-kun-dang-pharmaceutical-corp`)

## Provenance

Content hash: 0687e7595e2a890ab05cdc7a8d1684b0dc0521bb1859ad09d5f1f6afad2d375a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
